A phase 1 study investigating DX-2930 in healthy subjects

28Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Background: DX-2930 is a human monoclonal antibody inhibitor of plasma kallikrein under investigationfor long-term prophylaxis of hereditary angioedema. Objective: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DX-2930 in healthysubjects. Methods: A single-center, double-blinded study was performed in 32 healthy subjects randomized 3:1 toreceive a single subcutaneous administration of DX-2930 or placebo within 1 of 4 sequential, ascending dosecohorts (n = 8 each): 0.1, 0.3, 1.0, or 3.0 mg/kg. Results: No dose-limiting toxicity was observed. Headache was the most commonly reported treatmentemergent adverse event (AE), occurring at a rate of 25% in the DX-2930- and placebo-treated groups; nonewere severe and all resolved. There were no serious AEs, discontinuations owing to an AE, or deaths. Twosubjects had a severe AE reported as related to treatment by the blinded investigator; the 2 AEs wereasymptomatic creatinine phosphokinase elevations of 902 U/L in 1 subject receiving 0.1 mg/kg DX-2930 and1,967 U/L in 1 subject receiving placebo. For the 0.1-, 0.3-, 1.0-, and 3.0-mg/kg dose groups, respectively,mean maximum plasma concentrations were 0.6, 1.4, 5.6, and 14.5 mg/mL and mean elimination half-liveswere 20.6, 16.8, 17.6, and 21.2 days. Exploratory biomarker assays, involving ex vivo activation of the kallikreinpathway, showed dose- and time-dependent inhibition of plasma kallikrein, with evidence of sustainedbioactivity consistent with the pharmacokinetics profile. Conclusion: A single administration of DX-2930 in healthy subjects up to doses of 3.0 mg/kg was welltolerated without dose-limiting toxicity. Pharmacokinetic and pharmacodynamic data provide evidencefor a long-acting biological effect relevant to long-term prophylaxis for hereditary angioedema withC1-inhibitor deficiency.Trial Registration: ClinicalTrials.gov identifier: NCT01923207.

Cite

CITATION STYLE

APA

Chyung, Y., Vince, B., Iarrobino, R., Sexton, D., Kenniston, J., Faucette, R., … Adelman, B. (2014). A phase 1 study investigating DX-2930 in healthy subjects. Annals of Allergy, Asthma and Immunology, 113(4), 460-466.e2. https://doi.org/10.1016/j.anai.2014.05.028

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free